Impact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620175
Title:
Impact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK.
Authors:
Loncaster, Juliette A; Armstrong, Anne C; Howell, Sacha J; Wilson, Gregory; Welch, Richard; Chittalia, Abbas; Valentine, W; Bundred, N
Abstract:
The National Institute for Health and Clinical Excellence (NICE) recommended the Oncotype DX(®) Breast Recurrence Score(®) (RS) assay as an option for informing adjuvant chemotherapy decisions in node-negative, oestrogen receptor (ER)+, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer assessed to be at intermediate risk of recurrence based on clinicopathological factors. We evaluated the impact of RS testing on adjuvant chemotherapy decision-making in routine clinical practice in a UK Cancer Network.
Affiliation:
The Christie Hospital, Department of Medical Oncology, 550 Wilmslow Rd, Manchester, M20 4BX
Citation:
Impact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK. 2017, Eur J Surg Oncol
Journal:
European Journal of Surgical Oncology
Issue Date:
9-Jan-2017
URI:
http://hdl.handle.net/10541/620175
DOI:
10.1016/j.ejso.2016.12.010
PubMed ID:
28111076
Type:
Article
Language:
en
ISSN:
1532-2157
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLoncaster, Juliette Aen
dc.contributor.authorArmstrong, Anne Cen
dc.contributor.authorHowell, Sacha Jen
dc.contributor.authorWilson, Gregoryen
dc.contributor.authorWelch, Richarden
dc.contributor.authorChittalia, Abbasen
dc.contributor.authorValentine, Wen
dc.contributor.authorBundred, Nen
dc.date.accessioned2017-03-04T19:41:54Z-
dc.date.available2017-03-04T19:41:54Z-
dc.date.issued2017-01-09-
dc.identifier.citationImpact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK. 2017, Eur J Surg Oncolen
dc.identifier.issn1532-2157-
dc.identifier.pmid28111076-
dc.identifier.doi10.1016/j.ejso.2016.12.010-
dc.identifier.urihttp://hdl.handle.net/10541/620175-
dc.description.abstractThe National Institute for Health and Clinical Excellence (NICE) recommended the Oncotype DX(®) Breast Recurrence Score(®) (RS) assay as an option for informing adjuvant chemotherapy decisions in node-negative, oestrogen receptor (ER)+, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer assessed to be at intermediate risk of recurrence based on clinicopathological factors. We evaluated the impact of RS testing on adjuvant chemotherapy decision-making in routine clinical practice in a UK Cancer Network.en
dc.language.isoenen
dc.rightsArchived with thanks to European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncologyen
dc.titleImpact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK.en
dc.typeArticleen
dc.contributor.departmentThe Christie Hospital, Department of Medical Oncology, 550 Wilmslow Rd, Manchester, M20 4BXen
dc.identifier.journalEuropean Journal of Surgical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.